ArticleImmunity, inflammation and disease2025
Diagnostic and Prognostic Value of Serum Golgi Protein 73 in Patients With Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluating the diagnostic and prognostic utility of serum DLL1 in acute-on-chronic liver failure patients with bacterial infections.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
aimsThe prognosis and severity of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) cannot be well-identified by serum biomarkers. The present study aims to determine the role of serum Golgi protein 73 (GP73) in predicting the prognosis and severity of liver necrotizing inflammation induced by HBV-ACLF.
methodsA total of 427 chronic HBV-infected patients were included for the present study. Among these patients, 179 patients had chronic hepatitis B (CHB), 96 patients had HBV-related liver cirrhosis (LC), and 152 patients had HBV-ACLF. The baseline and dynamic changes in serum GP73 levels were measured and compared in CHB, LC and HBV-ACLF patients.
resultsThe serum GP73 levels were significantly greater in HBV-ACLF patients when compared to CHB and LC patients. Furthermore, serum GP73 demonstrated excellent performance in distinguishing HBV-ACLF from CHB and LC, with an area under the curve of 0.969 and 0.824, respectively. In the logistic regression analysis, a high GP73 level was identified as an independent risk factor associated with death within 3 months, and the optimal cut-off level was 274.59 ng/mL. The serum GP73 levels significantly decreased and remained stable at approximately 6 months for survivors.
conclusionSerum GP73 may serve as a valuable biomarker for the diagnosis and prognosis prediction of HBV-ACLF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.